Clinical Trial Update: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated whether adding lestaurtinib to standard chemotherapy improves outcomes in children with newly diagnosed acute lymphoblastic leukemia; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Leukemia
• Undifferentiated Leukemia

Drugs mentioned

• Lestaurtinib (CEP-701) (Lestaurtinib)

Snippet

Sponsor: Children's Oncology Group | Conditions: Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2018-12-10